⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25093 | 0.72 | — | — | |
| SCHEMBL3234935 | 0.71 | CYP1A2 (0.60) | — | |
| SCHEMBL618158 | 0.70 | ALDH1A1 (0.50) | — | |
| SCHEMBL27990801 | 0.69 | CYP1A2 (0.52) | — | |
| SCHEMBL2452711 | 0.69 | — | — | |
| SCHEMBL682 | 0.69 | — | — | |
| SCHEMBL27549515 | 0.69 | — | — | |
| SCHEMBL5146917 | 0.69 | — | — | |
| SCHEMBL13983442 | 0.69 | — | — | |
| SCHEMBL8463343 | 0.69 | GAA (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355654-A1 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230002768-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF ALPHA-1 ANTITRYPSIN | Arrowhead Pharmaceuticals, Inc. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11534453-B2 | RNAi therapy for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11384355-B2 | Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin | Arrowhead Pharmaceuticals, Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210052624-A1 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10858658-B2 | Compositions and methods for inhibiting gene expression of factor XII | Arrowhead Pharmaceuticals, Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10806750-B2 | RNAi therapy for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190284558-A1 | Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10308941-B2 | Compositions and methods for inhibiting gene expression of factor XII | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20090048410-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090023890-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-01-22 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080287628-A1 | Endosomolytic Poly(Vinyl Ether) Polymers | Arrowhead Madison Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Pharmaceuticals, Inc. | 2008-06-26 | — | — | US | disclosed |
| WO-2008022309-A2 | POLYCONJUGATES FOR IN VIVO DELIVERY OF POLYNUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (US) | 2008-02-21 | — | — | WO | disclosed |